COMMON STOCK PURCHASE WARRANT INMUNE BIO Inc.Common Stock Purchase Warrant • September 16th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 16, 2025 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 16, 2030, unless accelerated pursuant to Section 5 herein (the “Termination Date”), but not after the Termination Date, to subscribe for and purchase from INmune Bio Inc., a Nevada corporation (the “Company”), up to [______] shares of common stock, par value $0.001 per share (the “Common Stock”) of the Company (as subject to adjustment hereunder, the “Warrant Shares”), provided, however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in
ContractPlacement Agency Agreement • September 16th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”) and INmune Bio Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Common Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the “Purchase Agreement”), shall be collectively referred to herein as the “Tra
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 16th, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 12, 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
